このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Initial Safety and Preliminary Efficacy of the Novelrad Vascular Closure System (NVCS)

2026年9月29日 更新者:Novelrad Ltd.

A First in Human (FIH) Clinical Study to Evaluate the Initial Safety and Preliminary Efficacy of the Suture-Mediated Novelrad Vascular Closure System

This study evaluates the initial safety and preliminary efficacy of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths.

調査の概要

詳細な説明

The Novelrad Vascular Closure System (NVCS) is an investigational suture-mediated vascular closure device intended for use following percutaneous interventional catheterization procedures performed through the common femoral artery using large-bore procedural sheaths. The NVCS is designed to facilitate percutaneous closure of the arteriotomy using a continuous suture technique.

The study is being conducted to evaluate the initial safety and preliminary efficacy of the NVCS in subjects undergoing percutaneous interventional catheterization procedures using large-bore procedural sheaths.

研究の種類

介入

入学 (実際)

15

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Jerusalem、イスラエル
        • Hadassah Medical Center
      • Jerusalem、イスラエル
        • Shaare Zedek Medical Center
      • Tel Aviv、イスラエル
        • Sourasky Tel-Aviv Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Subject is ≥18 years old.
  2. Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
  3. Subject has suitable sized vessel / calcification as evaluated on pre-procedural CT angiography by the investigator and by the study' screening committee
  4. Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
  5. Understand and sign the study specific written informed consent form
  6. Able and willing to fulfill the follow-up requirements

Exclusion Criteria:

Baseline Exclusions:

  1. Known to be pregnant or lactating.
  2. Immunocompromised or with pre-existing autoimmune disease.
  3. Systemic infection or a local infection at or near the access site.
  4. Significant anemia (Hgb < 9 g/dL hematocrit <30%).
  5. Morbidly obese or cachectic (BMI >40 kg/m2 or <20kg/m2).
  6. Known bleeding disorders including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability.
  7. Known allergy to any device component.
  8. Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
  9. Common femoral artery with calcium, as determined by baseline CTA, precluding safe access in the opinion of the investigator or severe peripheral vascular disease as evidenced by severe claudication when ambulating < 30 meter, weak or absent pulses in the affected limb.
  10. Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
  11. Prior target artery closure with any closure device < 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
  12. Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
  13. Undergoing therapeutic thrombolysis.
  14. Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR >1.8 at the time of the procedure.
  15. Subject unable to be adequately anti-coagulated for the procedure.
  16. Subjects who are not mobile and are confined to a wheelchair or bed.
  17. ST-elevation MI within 45 days prior to procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
  18. NYHA class IV heart failure.
  19. Left ventricular ejection fraction <20%.
  20. Unilateral or bilateral lower extremity amputation.
  21. Renal insufficiency (serum creatinine >2.5 mg/dl) or on dialysis therapy, or after renal transplant.
  22. Existing nerve damage in the NVCS treated leg.
  23. Further planned endovascular procedure within the next 30 days.
  24. Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
  25. Subject cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
  26. Common femoral artery <6mm or >50% diameter femoral stenosis by baseline CTA and/or severe peripheral arterial disease or Rutherford Classification 5 or 6.
  27. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  28. Known severe allergy to contrast reagent that cannot be managed with premedication.
  29. Connective tissue disease (e.g., Marfan's Syndrome).
  30. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure.
  31. Subject is mentally incompetent or a prisoner.
  32. Planned antegrade puncture during the index procedure.
  33. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
  34. Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed).

Intra-Procedure Exclusions:

  1. On baseline Duplex US the Common femoral artery <6mm or >50% stenosis of the femoral artery.
  2. Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
  3. Common femoral artery suspected to have experienced a back wall puncture or underwent > one (1) arterial puncture during the catheterization procedure.
  4. Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device.
  5. Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
  6. Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
  7. Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
  8. Planned antegrade puncture during the index procedure.
  9. Possible bacterial contamination of the procedure's sheath or surrounding tissues during the procedure.
  10. Intra-procedural complication(s) at the femoral access site before procedural sheath removal and before sliding the NVCS knot down, including: 1. Bleeding or swelling around the sheath that may indicate hematoma formation and/or pseudoaneurysm formation; and 2. Peri-procedural duplex us/angiographic evidence of thrombus formation or significant injury in the aorta or iliac vessels associated with procedural large bore sheath placement and/or sub-optimal anticoagulation.
  11. Presence of ipsilateral femoral venous sheath during the interventional procedure.
  12. Systolic blood pressure <90 mm Hg just prior to planned vascular closure without the ability to increase it.
  13. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  14. Index procedure planned sheath or interventional device >22Fr during the procedure.
  15. Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCS.
  16. Duplex US (or by angiography if applicable) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.
  17. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Novelrad Vascular Closure System (NVCS)

The Novelrad Vascular Closure System (NVCS), will be used in subjects who are undergoing diagnostic or interventional catheterization procedures

NVCS will be used to close the common femoral artery access site while reducing time-to-hemostasis in subjects who have undergone diagnostic or interventional catheterization procedures using 8-22 French (F) Sheaths.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety: Freedom from major complications of the target limb within 30 days following the procedure
時間枠:Within 30 days post-procedure

Assessment of the incidence of protocol defined major complications of the target limb access site through 30 days post procedure as specified in the protocol.

Within 30 days post-procedure
Efficacy: Mean Time to Hemostasis
時間枠:Periprocedural

The Time to Hemostasis is defined as the elapsed time between withdrawal of index procedure sheath from common femoral artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).

Periprocedural

二次結果の測定

結果測定
メジャーの説明
時間枠
Safety: Frequency of minor complications at the target limb.
時間枠:Within 30 days post procedure

Assessment of the incidence of minor complications of the target limb access site as specified in the protocol.

Within 30 days post procedure
Efficacy: Technical Success
時間枠:Periprocedural

Achievement of hemostasis with the NVCS without the need for any access-site-related adjunctive surgical or endovascular intervention (target limb only).

Periprocedural
Efficacy: Treatment/Procedure Success
時間枠:Within 30 days post procedure

Subjects with technical success and free from major complications through 30 days follow-up.

Within 30 days post procedure
Efficacy: Mean Time for NVCS Procedure
時間枠:Periprocedural

The elapsed time from initial skin break (first needle insertion) to time when the suture is released from the NVCD plus the elapsed time from performing the knot at the end of the index procedure and until hemostasis is achieved.

Periprocedural
Efficacy: Mean Time to Ambulation
時間枠:Within 24 hours after procedural sheath removal

The elapsed time between last procedural sheath removal and when ambulation is achieved (subject is standing and walking at least 6-meters without bleeding).

Within 24 hours after procedural sheath removal
Time-to-discharge eligibility
時間枠:Within 48 hours after the procedure

The time following the removal of the NVCS and when the patient is eligible for discharge based solely on (1) completion TTA, (2) freedom from orthostatic hypotension [defined as stable blood pressure and heart rate after ambulating], (3) ability to void and, (4) a stable access site without bleeding or expansion of a prior hematoma.

Within 48 hours after the procedure
Efficacy: Percent of subjects with surgical or endovascular intervention post closure
時間枠:Periprocedural

Subjects require adjunctive surgical or endovascular intervention to achieve hemostasis of the NVCS access site.

Periprocedural
Efficacy: Percent of subjects with NVCS Failure
時間枠:Periprocedural

When the device is used in accordance with the IFU, but does not perform as described in the IFU, and/or negatively impacts treatment of the study subject.

Periprocedural

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Yossi Muncher, Ph.D.、Novelrad Ltd.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月30日

一次修了 (実際)

2026年8月18日

研究の完了 (実際)

2026年8月18日

試験登録日

最初に提出

2026年9月17日

QC基準を満たした最初の提出物

2026年9月29日

最初の投稿 (実際)

2026年10月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NVCS-CLN-001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する